2. TGF-beta/Smad
  3. TGF-β Receptor
  4. Stamulumab

Stamulumab  (Synonyms: MYO-029)

Cat. No.: HY-P99588 Purity: 95.07%
SDS COA

Molarity Calculator

Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research.

For research use only. We do not sell to patients.

CAS No. : 705287-60-1

Size Price Stock Quantity
1 mg USD 240 In-stock
5 mg USD 620 In-stock
10 mg USD 990 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Stamulumab Related Antibodies

Top Publications Citing Use of Products

View All TGF-β Receptor Isoform Specific Products:

View All Isoforms
ALK1 ALK2 ALK3 ALK4 ALK5 ALK6 ALK7 TGFβR2 ACVR2A ACVR2B

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research[1][2].

Isotype

Human IgG1 lambda1
Recommend Isotype Controls
Species

Human
In Vivo

Stamulumab (MYO-029; ip; 1-10 mg/kg/week for 12 weeks) increases skeletal muscle mass in vivo in a concentration-dependent manner in SCID mice. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia[1].
Stamulumab (i.v.; 1, 5, 20, 100 mg/kg/week for 4 weeks) has a central clearance (CL) of 0.25 mL/h/kg in C57/SCID mice[1].
Pharmacokinetic Parameters of Stamulumab (MYO-029)[1].

C57/SCID mice IV (1-100 mg/kg/week for 4 weeks) Sprague Dawley rats (2-50 mg/kg; single injection) Cynomolgus monkeys (10-100 mg/kg/week for 5 or 39 weeks)
CL (mL/h/kg) 0.245 0.542 0.228
Volume of central compartment (mL/kg) 103 58.9 41.8
Distributive clearance (mL/h/kg) 1.79 0.815

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female SCID mice[1]
Dosage: 1, 2.5, 5, 10 mg/kg
Administration: IP; every week for 12 weeks
Result: Increased skeletal muscle mass in vivo in a concentration‐dependent manner.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Stamulumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 lambda2
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Stamulumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Stamulumab705287-60-1MYO-029MYO029MYO 029TGF-β ReceptorTransforming growth factor beta receptorsIgG1λmyostatinActRIIBmuscle fiber hypertrophyBecker muscular dystrophyBMDfacioscapulohumeral dystrophyFSHDlimb-girdle muscular dystrophyLGMDInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Stamulumab
Cat. No.:
HY-P99588
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.